Innovators Circle: Navigating Regulatory Pathways for XR Therapeutics

Join Scott Xiao, Co-Founder and CEO of Luminopia, for a discussion on the evolving regulatory landscape for extended reality (XR) technologies in healthcare. As the first company to receive U.S. Food and Drug Administration clearance for a prescription virtual-reality therapeutic, Luminopia has helped define how immersive technologies can move from experimental concepts to regulated medical treatments.

In this session, Scott will explore the regulatory pathways that XR developers must navigate to bring patient-facing digital therapeutics to market. Drawing on real-world experience from developing and commercializing a VR-based treatment for amblyopia, the talk will cover key considerations including clinical trial design, hardware considerations, safety and usability requirements, and real-world outcomes.

Whether you’re developing immersive healthcare applications, navigating regulatory strategy, or exploring how XR can improve patient outcomes, this session will provide practical insights into translating cutting-edge technology into regulated medical products.